BIRC5 and familial pancreatic carcinoma: In a recent study, Chang et al. demonstrated that exosomes in the serums of patients with PDAC harbouring KRAS mutations were carrying high amounts of survivin, as did KRAS-transformed fibroblasts and pancreatic cancer cells [47].